Media Doctor Canada
Follow us on Twitter








"AstraZeneca drug gets boost in cholesterol wars"

Globe and Mail

Source: Globe and Mail

Published: 31 Mar 2022

Category: Pharmaceutical

Rating: (1½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

LONDON - AstraZeneca Plc is stopping a clinical trial of its blockbuster cholesterol fighter Crestor early because of the clear benefits of the medicine compared to placebo, the company said on Monday.
The news is a boost for Crestor, the group's third biggest seller, in an increasingly competitive anti-cholesterol market. It comes as doubts deepen over the value of Vytorin, a rival drug from Schering-Plough Corp and Merck & Co.
"It's a very fortuitous combination for AstraZeneca," said Nomura Code analyst Paul Diggle...

The original article can found in the Media Doctor archives.

how did it rate? (more information)

Criteria Rating
Total Score 3 of 10
Availability of Treatment Not Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Not Satisfactory (?)
Quantification of Benefits of Treatment Not Satisfactory (?)
Harms of Treatment Not Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Not Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

Media Doctor typically doesn't evaluate stories which are substantially of a business nature but we made an exception in this case because the story does make claims related to the drug in question. While the lead to this story would raise some excitement, the story itself answers none of the important questions around the clinical trial of this drug which would be of interest to patients. We get no information about the evidence, the benefits and harms related to the treatment and the sources of information. This is a wire story and no effort was made to Canadianize the content so we also get no information about availability or costs of the treatment. The message in this story is that it is probably a good thing to buy the stock of the manufacturer of this drug, but unfortunately there isn't much that will help anybody decide on what medication is best to take or even if they need medication at all.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada